Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NST 628

Next Previous
Drug Profile

NST 628

Alternative Names: NEST-1; NST-628

Latest Information Update: 31 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nested Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Ras Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 25 Aug 2026 Nested Therapeutics plans a phase 0/I trial for Glioma (Recurrent, Late-stage disease; Second-line therapy or greater) in USA in October 2026 (PO) (NCT07784985)
  • 17 Apr 2026 Efficacy, pharmacodynamics, pharmacokinetics and adverse event data from a phase I trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 17 Apr 2026 Efficacy and adverse event data from a phase I trial in Solid tumours released by Nested Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top